Juvaris BioTherapeutics, Inc. is developing novel, adjuvanted vaccines and immunotherapeutics to treat infectious disease and cancer.
The Company's platform technology induces profound immunostimulation via cationic lipid-DNA (non-coding) complexes (CLDC). The Company's lead product candidate, JVRS-100, stimulates adaptive and innate immune responses at levels many fold higher than other drugs in its class. JVRS-100 is in clinical development as a vaccine adjuvant and an immunotherapeutic.
Adjuvanted Vaccine Development
- JVRS-100 is being developed as an adjuvant to improve the effectiveness of available vaccines and to develop novel vaccines against otherwise untreatable diseases.
- Adjuvants enhance the effect of vaccines by increasing the quantity and quality of the immune response and reducing the amount of antigen required in the vaccine.
- JVRS-100 is being developed as an immunotherapeutic to treat infectious disease and cancer.
- JVRS-100 has been shown to induce significant innate immunity resulting in anti-viral, anti-bacterial and anti-cancer effects.
Juvaris has completed two major fundraising rounds from leading venture capitalists, including a recently completed Series B financing that comprised of Kleiner Perkins Caufield & Byers, SV Life Sciences and a strategic corporate investor. Juvaris has also obtained substantial research support through grants from the National Institutes of Health and from an array of distinguished academic collaborators. The Company also has a worldwide strategic alliance with Bayer HealthCare AG for the use of its technology in the field of animal health.
^ back to top